The Breast Center’s Dr. Linda Vahdat discussed the TM copper depletion clinical trial on WFMZ-TV news in Allentown, PA. View the video below.
Click here to watch the video.
Below is a complete list of open clinical trials at the Weill Cornell Breast Center. Click on the study name to read detailed information about the study. To find out more about our clinical trials or to make an appointment at the Breast Center, please call (212) 821-0644.
Supportive Care/Non-Treatment Studies
|Study Name||Goal of Study||Eligibility|
|Cold Cap Study||Preventing hair-loss using the Cold Cap during Taxotere/Cytoxan (TC)||-Early Stage Breast Cancer-Begins with TC chemotherapy|
|Glutamine Study||Reducing peripheral neuropathy using glutamine||-Grade 1 or above neuropathy-During or after Taxol or Abraxane.|
|Herceptin Cardiotoxicity||Evaluating variations in DNA sequencing (SNPs) on risk of Herceptin-related heart failure||-Congestive heart failure-Decline in ejection fraction by 15%|
|Rakhi Study||To study how breast tumors develop blood vessels||-Blood samples during treatment-Already underwent surgery|
|Study Name||Goal of Study||Eligibility|
|GALENA||A vaccine trial: evaluating NeuVax in preventing breast cancer recurrence.||-HER2 1+/2+, node positive-Completed standard treatment with surgery, chemo, radiation.|
|PUMA||To study the benefit of two new drugs: Temsirolimus plus Neratinib in metastatic HER2 or TNBC*||-No more than 4 prior chemo regimen-Received Herceptin in the past-No concurrent use of hormone therapy|
|RxSPONDER||To study how hormone therapy work with or without chemotherapy in breast cancer||-Hormone Positive, HER2 negative-Oncotype <25, 1-3 lymph node positive|
|BEACON||New generation TOPO1 inhibitor NKTR-102 (targets tumor DNA) in recurrent or metastatic breast cancer||-Already received 2-5 prior regimens-Already received Taxane, anthracycline, Xeloda, Herceptin (if HER2 +), and hormone therapy (if ER+)|
|IMMU-132||To study the effectiveness of antibody RS7 attached to SN38, a metabolite of Irinotecan||-Already received 1-3 prior regimens-Active disease on CT or MRI|
|OPTIMER||Immunotherapy with OPT-822 in metastatic breast cancer||-Stable disease, partial response, or complete response after 1 regimen|
|ALLIANCE||Using Panobinostat (blocks enzymes needed for cell growth) and Letrozole in TNBC*||-TNBC* with metastatic disease|
|177-J591||Using an antibody J591 linked to radioactive molecule 177Lu, to target tumor blood vessels||-Metastatic breast cancer-Already received standard therapy|
|SYNTA||Using Ganetespib, a small molecule inhibitor against Hsp90 protein, to stop tumor growth||-Previously untreated metastatic, HER2 positive, or TNBC*.|
|LUX-Breast 1||Using Afatinib (inhibits growth factor receptor) plus Navelbine vs. Herceptin plus Navelbine to stop tumor growth||-HER2 positive, metastatic disease-Failed one prior treatment-No prior Navelbine|
|BKM120||Using BKM120 (inhibit tumor growth and survival by blocking PI3K pathway) with fulvestrant, to enhance cancer cell death||-Metastatic, Hormone positive-HER2 negative-Progressed on or after aromatase inhibitor|
|NCI8264||Using PARP inhibitor ABT-888 (interfere with tumor DNA repair) alone or with Carboplatin||-Metastatic BRCA-associated breast cancer|
|TM||Using TM (copper depletion) to prevent recurrence in moderate to high risk patients||-Metastatic no active disease-Stage 2 and above TNBC*.|
*TNBC = Triple Negative Breast Cancer
Researchers at Weill Cornell Medical College have recently published the results of a Phase II clinical trial conducted at the Weill Cornell Breast Center. The results show that an anti-copper drug called tetrathiomolybdate (TM) that disables the ability of bone marrow cells from setting up a “home” in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in treating high-risk triple-negative breast cancer, one of the most difficult-to-treat forms of cancer.
The median survival for metastatic triple-negative breast cancer patients is historically nine months. However, the results of the study, recently published in the Annals of Oncology, show that if patients at high-risk of relapse with no current visible breast cancer are copper depleted, it results in a prolonged period of time with no cancer recurrence. Only two of 11 study participants with a history of advanced triple-negative breast cancer relapsed within 10 months after treatment with tetrathiomolybdate (TM).
“These study findings are very promising and potentially a very exciting advance in our efforts to help women who are at the highest risk of recurrence,” says the study’s senior investigator, Dr. Linda Vahdat, director of the Breast Cancer Research Program, chief of the Solid Tumor Service and Professor of Medicine at Weill Cornell Medical College.
Four of the study participants with a history of metastatic triple-negative breast cancer have had long-term benefit remaining disease free for between three and five and a half years.
“The anti-copper compound appears to be keeping tumors that want to spread in a dormant state,” reports Dr. Vahdat. “We believe one of the important ways it works is by affecting the tumor microenvironment, specifically the bone marrow-derived cells that are critical for metastasis progression.”
In addition, study participants with other forms of high-risk for relapse breast cancers — either stage 3 or stage 4 — without evidence of disease after treatment have also fared well. The progression-free survival rate among these 29 patients in the study has been 85 percent, to date.
“As good as these interim findings look to us, we cannot talk about significant benefit until we compare TM treatment to other therapies,” she says. Dr. Vahdat expects to launch a phase III randomized clinical trial in the near future.
This research is a report of the first 40 patients. The clinical trial, which began in 2007, has been expanded many times and now includes 60 patients, more than half of who have triple-negative breast cancer.
“Taking Tamoxifen 5 years vs. 10 Years”
The Weill Cornell Breast Center is hosting a seminar on the latest news from the San Antonio Breast Cancer Conference regarding treatment after breast cancer.
WHEN: Thursday, January 17, 2013
WHERE: 1305 York Avenue (at 70th Street) 2nd Floor, Conference Room B
Refreshments will be served.